Codagenix
is a New York-based biotechnology company that researches and develops viral therapeutics for the treatment of cancer and infectious diseases... Read moreCodagenix
is a New York-based biotechnology company that researches and develops viral therapeutics for the treatment of cancer and infectious diseases... Read more
News
Jul 22, 2025
Benzinga
Codagenix: Codagenix Awarded PATH Subcontract to Develop Stabilized Novel Oral Polio Vaccine Candidates
Oct 30, 2024
OINDPnews
Codagenix: AuraVax gets BARDA contract to test its NanoSTING-002 mucosal adjuvant with Codagenix's intranasal flu vaccine
Oct 24, 2023
BioSpace
Codagenix: Codagenix Receives Additional Award from US Department of Defense to Advance Development of Dengue Vaccine
Oct 11, 2023
Yahoo
Codagenix: Codagenix Announces Late-Breaking Presentation of Positive Clinical Immunogenicity Data For COVID-19 Vaccine Candidate CoviLiv at IDWeek 2023
Oct 04, 2023
OINDPnews
Codagenix: Codagenix gets BARDA funding for Phase 2b trial of CoviLiv intranasal vaccine against COVID-19
Aug 30, 2023
Pharamceutical Technology
Codagenix: Codagenix pursues RSV vaccine development amid unexpected challenges
May 13, 2023
Drug Discovery and Development
Codagenix: Codagenix taps synthetic biology and machine learning in vaccine development
May 10, 2023
OINDPnews
Codagenix: Codagenix initiates pediatric Phase 1 trial of CodaVax-RSV intranasal vaccine for the prevention of RSV
Feb 17, 2023
OINDPnews
Codagenix: Codagenix raises $25 million for development of CodaVax-RSV intranasal vaccine against RSV
Oct 26, 2022
Yahoo
Codagenix: Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
